Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue-
EPS-$0.83Miss by $0.15
EPS estimate-$0.68

Next report

Nov 11, 2026 (in a month)
EPS estimate-$0.54

Financials

Q1 2025

Income statement

See full
Revenue--100%
Operating income-$22.2M-53.0%
Net income-$20.3M-45.5%
EPS (diluted)-$0.83+95.2%

Balance sheet

See full
Cash & equivalents$30.9M-36.3%
Total debt$14.0M—
Total equity$168.8M+197%
Total assets$191.3M—

Cash flow

See full
Operating cash flow-$19.8M-31.5%
CapEx$511.0K+2,739%
Free cash flow-$20.4M-34.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$73.09M—
Enterprise value$56.22M—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio13.9×—

FAQ

When did Artiva Biotherapeutics, Inc. report Q1 2025 earnings?
Artiva Biotherapeutics, Inc. (ARTV) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Artiva Biotherapeutics, Inc.'s Q1 2025 revenue and EPS?
Artiva Biotherapeutics, Inc. reported revenue of - and eps of $-0.83 for Q1 2025.
Did Artiva Biotherapeutics, Inc. beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.68 by $0.15.
How did Artiva Biotherapeutics, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $251.0K a year earlier and eps grew 96.2% from $-22.00.
Where can I find Artiva Biotherapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-066416) and the 10-Q periodic report (0000950170-25-066421) directly on SEC EDGAR. The filing index links above go to sec.gov.